Open Access Open Access  Restricted Access Subscription Access

Effect of Perioperative β-Blockers on Pulmonary Complications among Patients with Chronic Obstructive Pulmonary Disease Undergoing Lung Resection Surgery


Affiliations
1 Long Island Pulmonary and Sleep Associates, 200 North Village Avenues, Suite 300, Rockville Centre, NY 11750-5294, United States
2 Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States
 

The aim of this study is to determine if COPD patients undergoing lung resection with perioperative β-blocker use are more likely to suffer postoperative COPD exacerbations than those that did not receive perioperative β-blockers. Methods: A historical cohort study of COPD patients, undergoing lung resection surgery at Memorial Sloan-Kettering Cancer Center between 2002 and 2006. Primary outcomes were the rate of postoperative COPD exacerbations, defined as any initiation or increase of glucocorticoids for documented bronchospasm. Results: 520 patients with COPD were identified who underwent lung resection. Of these, 205 (39%) received perioperative β-blockers and 315 (61%) did not. COPD was mild among 361 patients (69% of all patients), moderate in 117 patients (23%), and severe in 42 patients (8%). COPD exacerbations occurred among 11 (5.4%) patients who received perioperative β-blockers and among 20 (6.3%) patients who did not. Secondary outcomes, which included respiratory failure, 30-day mortality, and the presence or absence of any cardiovascular complication, ICU transfer, cardiovascular complication, or readmission within 30 days, did not differ in prevalence between the two groups. Conclusions: This study implies that perioperative β-blockers use among COPD patients undergoing lung resection surgery does not impact the rate of exacerbations.
User
Notifications
Font Size

Abstract Views: 76

PDF Views: 0




  • Effect of Perioperative β-Blockers on Pulmonary Complications among Patients with Chronic Obstructive Pulmonary Disease Undergoing Lung Resection Surgery

Abstract Views: 76  |  PDF Views: 0

Authors

A. Kamath
Long Island Pulmonary and Sleep Associates, 200 North Village Avenues, Suite 300, Rockville Centre, NY 11750-5294, United States
D. E. Stover
Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States
A. Hemdan
Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States
I. Belinskaya
Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States
R. M. Steingart
Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States
Y. Taur
Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States
M. B. Feinstein
Primary Research Institution, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-9809, United States

Abstract


The aim of this study is to determine if COPD patients undergoing lung resection with perioperative β-blocker use are more likely to suffer postoperative COPD exacerbations than those that did not receive perioperative β-blockers. Methods: A historical cohort study of COPD patients, undergoing lung resection surgery at Memorial Sloan-Kettering Cancer Center between 2002 and 2006. Primary outcomes were the rate of postoperative COPD exacerbations, defined as any initiation or increase of glucocorticoids for documented bronchospasm. Results: 520 patients with COPD were identified who underwent lung resection. Of these, 205 (39%) received perioperative β-blockers and 315 (61%) did not. COPD was mild among 361 patients (69% of all patients), moderate in 117 patients (23%), and severe in 42 patients (8%). COPD exacerbations occurred among 11 (5.4%) patients who received perioperative β-blockers and among 20 (6.3%) patients who did not. Secondary outcomes, which included respiratory failure, 30-day mortality, and the presence or absence of any cardiovascular complication, ICU transfer, cardiovascular complication, or readmission within 30 days, did not differ in prevalence between the two groups. Conclusions: This study implies that perioperative β-blockers use among COPD patients undergoing lung resection surgery does not impact the rate of exacerbations.